Last edition
News about "Curon Biopharmaceutical"
Merck to Acquire CN201 from Curon Biopharmaceutical
CN201 is currently being evaluated in Phase 1 and Phase 1b/2 clinical trials for treating patients with relapsed or refractory non-Hodgkin’s lymphoma (NHL) and relapsed or refractory B-cell acute lymphocytic leukemia (ALL), respectively.
Curon Biopharmaceutical | 14/08/2024 | By Aishwarya | 102
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members